Dr. Daniel D. Von Hoff, who has been instrumental in developing numerous new cancer treatments, is among this year’s recipients of the Award of Excellence from the Hope Funds for Cancer Research.Continue reading
Category Archives: AZBio News
Nearly 40 New Medicines in Development for Parkinson’s Disease
Washington, D.C. (March 24, 2014) — America’s biopharmaceutical research companies currently are developing 37 innovative new medicines to help the estimated 10 million people worldwide who are living with Parkinson’s disease. These medicines in development – all either in clinical trials or under review by the Food and Drug Administration (FDA) – include 23 for Parkinson’s disease, 11 for related conditions and 3 diagnostics, according to a new report by the Pharmaceutical Research and Manufacturers of America (PhRMA).Continue reading
ASU scientist Roy Curtiss receives Lifetime Achievement Award from ASM
Roy Curtiss III, a scientist at the Biodesign Institute at Arizona State University, has been selected as the 2014 recipient of the Lifetime Achievement Award from the American Society for Microbiology (ASM).Continue reading
HCR 2005 – “Right to Try” Won’t Benefit Patients
While well intentioned, State “Right to Try” bills are fraught with false hope and dangerous side effects.Continue reading
Castle Biosciences’ Non-Invasive Gene Expression Profile Test Shown to Identify Sentinel Lymph Node Negative Melanoma Patients at High Risk of Metastasis
Data presented at the Latest in Dermatology Research Symposia session of 72nd Annual Meeting of the American Academy of DermatologyContinue reading
TGen-led study discovers genetic cause of rare type of ovarian cancer
Scientific breakthrough could lead to new cancer treatments; study inspired by memory of 22-year-old patientContinue reading
FDA Approves Xolair(R) (omalizumab) for People with Chronic Idiopathic Urticaria (CIU), a Form of Chronic Hives
Xolair is the First Biologic Medicine Approved for CIU, a Burdensome Skin Condition that Can Cause Hives and Severe Itch and May Last Many Years. Nearly 50 Percent of Patients Have Inadequate Response to H1-antihistamines, Previously the Only Approved Therapy for CIU3. Approximately 1.5 Million People in U.S. have CIU.Continue reading
Opportunity Alert: VisionGate CLIA Lab Director
VisionGate is dedicated to saving lives through early cancer detection and prevention. The Cell-CT™ is a revolutionary automated 3D cell imaging platform that generates high-resolution 3D biosignatures from intact cells. They are currently recruiting for a CLIA Lab Director.Continue reading
UA Med Students in Phoenix Learn Next Destination at Match Day
Class of 37 from Downtown Phoenix Campus Will Be Fourth to GraduateContinue reading
TGen recognized as ‘2014 Economic Driver’ by Greater Phoenix Chamber of Commerce
GPCC Impact Awards recognize ability, tenacity and sense of communityContinue reading